ClinicalTrials.gg
RecruitingNCT07590531Updated Aug 10, 2026

AMT-116 in Combination With AK112 in Patients With Lung Cancer

A Phase 1/2 interventional study of AMT-116 and AK112 in Advanced Non-small Cell Lung Cancer (NSCLC), sponsored by Multitude Therapeutics Inc.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Multitude Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
118
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung — 23 open to participants now, 30 under way, 7 of them phase 3. ivonescimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
12th of 31
118 · median 70
Started
2026
with 15 others
Phase 1/2
6 of 31
4 open now
Primary completion
2027-05
later than 8 of 29 live
Registered
26th of 31
by date
Lead sponsor
1 of 31
Multitude Therapeutics Inc.

Among the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by planned enrollment, is one of 16 that started in 2026, is one of 6 in phase 1/2, reaches primary completion later than 8 of the 29 other live ones, and was the 26th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

23 of the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About ivonescimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Willing and able to provide written for this trial.
  2. At the time of screening, aged ≥18 years and ≤75 years.
  3. or cytologically confirmed locally advanced (Stage IIIB/III C) or (Stage IV) NSCLC that is not amenable to complete surgical resection and cannot be treated with curative concurrent or sequential chemoradiotherapy (according to the 8th edition of the International Union Against Cancer and the American Joint Committee on Cancer TNM staging for lung cancer).
  4. Stage Ib: Locally advanced/metastatic NSCLC; both subjects who have previously received systemic therapy and those who have not may be enrolled;

    Phase II: Each cohort must meet the following requirements:

    Cohort 1: Histologically or cytologically diagnosed with non-squamous NSCLC, EGFR wild-type, and ALK fusion-negative.

    Co-hort 2: Histologically or cytologically diagnosed with squamous-cell NSCLC, known to be EGFR wild-type and ALK fusion gene-negative.

    Co-hort 3: Histologically or cytologically diagnosed with non-squamous NSCLC and harboring an EGFR mutation.

  5. Subjects must have at least one (as defined by 1.1 criteria).
  6. (ECOG) performance status of 0 or 1.
  7. Expected survival of ≥12 weeks.
  8. Subjects' laboratory test results must meet the requirements.
  9. Women of (WCBP) must consent to the use of two effective methods during the study treatment period and for at least 12 weeks after the final administration of IMP
  10. Women of child-bearing potential (WCBP) must have a negative serum pregnancy test within seven days preceding the initial administration of the medicinal product (IMP).
  11. Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least 12 weeks after the last dose of the IMP.
  12. Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP.

Key Exclusion Criteria:

  1. Histopathological evidence of small cell lung cancer.
  2. For Cohort 1 and Cohort 2 of Phase II, patients must not have non-small cell lung cancer with known EGFR-sensitive mutations, ALK fusions, BRAF V600E mutations, ROS1 fusions, MET exon 14 skipping mutations, NTRK fusions, or RET fusions.
  3. Prior treatment with any 4v9-targeted therapy or an antibody-drug conjugate (ADC) based on a topoisomerase I inhibitor as the toxin.
  4. Received the following treatments or medications prior to the start of the study:

    i. Systemic anticancer therapy, including chemotherapy and biologics, within 3 weeks prior to the first dose; hormonal anticancer therapy or small-molecule targeted therapy within 2 weeks prior to the first dose; or Chinese herbal medicines or proprietary Chinese herbal preparations with anticancer indications within 2 weeks prior to the first dose. Received nonspecific immunomodulatory therapy (e.g., interleukins, interferons, thymosin, tumor necrosis factor, etc.) within 2 weeks prior to the first dose.

    ii. Received a live or attenuated vaccine within 4 weeks prior to the first dose.

    iii. Received radiation therapy within 3 weeks prior to the first dose. Palliative radiation therapy administered for symptom control at least 2 weeks prior to the first dose is permitted.

  5. Received systemic therapy (including but not limited to , cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to the first dose.
  6. Adverse reactions from prior treatment have not yet resolved to Grade 1 or less.
  7. Subjects who have experienced an immune-related adverse event (irAE) requiring permanent discontinuation of treatment, or a Grade 3 or higher irAE, or a cardiac, neurological, or ocular irAE of any grade (including Grade 2 immune-related pneumonia, but excluding Grade 3 hypothyroidism that can be controlled with hormone replacement therapy).
  8. Known symptomatic or other central nervous system (CNS) metastases, or brain metastases or other CNS metastases that the investigator deems to require treatment but have not been treated. Subjects with asymptomatic brain metastases or a history of brain metastases that have been stable for ≥2 weeks prior to the first dose may be eligible for this study, provided they meet all of the following criteria: no metastases to the meninges, midbrain, pons, cerebellum, medulla oblongata, or spinal cord, or spinal cord compression; discontinuation of hormonal therapy for more than 2 weeks prior to the first dose; imaging studies performed within at least 4 weeks show no evidence of new or enlarged brain metastases.
  9. History of other than the enrollment diagnosis within 5 years prior to the first administration of the study drug.
  10. Underwent major surgery within 4 weeks prior to the first administration of the study drug, or has not fully recovered from surgery; or sustained a major traumatic injury within 4 weeks prior to the first administration; or is scheduled to undergo surgery during the anticipated duration of study participation or within 4 weeks after the last administration.
  11. History of interstitial lung disease (ILD) or non-infectious pneumonia requiring steroid therapy; current ILD/pneumonia; suspected ILD/pneumonia (e.g., idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, idiopathic pneumonia, etc.); or other pulmonary diseases that significantly impair lung function at baseline.
  12. History of active disease or a history of autoimmune disease requiring systemic treatment within the past 2 years.
  13. Current or past history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
  14. History of hypertensive crisis or hypertensive encephalopathy.
  15. Subjects with severe coagulation disorders or other evidence of significant bleeding risk.
  16. Uncontrolled pleural effusion or ascites requiring repeated drainage within 4 weeks prior to the first dose.
  17. Active infection treated with systemic antimicrobial therapy within 2 weeks prior to the first dose. Severe infection occurring within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia.
  18. History of abdominal fistula, tracheoesophageal fistula, or female genital fistula (e.g., vesicovaginal fistula, ureterovaginal fistula, and vesicovaginal fistula), gastrointestinal perforation, or abdominal abscess; or if the investigator considers the subject to have risk factors for gastrointestinal obstruction. If the fistula or perforation has been treated by resection or repair, and the investigator assesses that the condition has fully resolved, the subject may be enrolled.
  19. The subject has uncontrolled comorbidities, including but not limited to poorly controlled hypertension or diabetes, psychiatric disorders, or conditions that may limit study compliance, or other comorbidities or conditions that the investigator believes may affect study judgment or interfere with the completion of study procedures and follow-up examinations.
  20. Known immunosuppressive disease or (HIV) infection.
  21. Patients who are positive for surface antigen (HBsAg) and/or virus (HCV) antibodies at screening are ineligible for enrollment, unless hepatitis B virus (HBV) DNA levels and HCV RNA testing clearly rule out active infection requiring antiviral treatment for hepatitis B or C (HBV DNA ≥ 1000 cps/mL or 200 IU/mL).
  22. Known active tuberculosis (TB); suspected active tuberculosis must be ruled out by clinical examination.
  23. History of allogeneic organ transplantation or hematopoietic stem cell transplantation, excluding corneal transplantation.
  24. Known immediate-type or delayed-type to the study drug, a history of allergic reactions, or allergy to any component of the study drug or .
  25. Pregnancy (positive β-human chorionic gonadotropin [β-hCG] test) and lactating women.
  26. The subject is unwilling or unable to comply with the protocol.
  27. The subject requires the use of a potent inhibitor within one week prior to dosing or during the study.
  28. Any other disease, metabolic disorder, physical examination findings, or clinical laboratory results that raise suspicion of to the study drug, or that may affect the subject's safety, the interpretation of study results, or place the subject at high risk of complications.

    -

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Phase I: Dose escalation

    Three dose levels in the Phase I part of the study

    Drug: AMT-116 · Drug: AK112

  • Other
    Phase II: Dose Expansion

    Patients in phase II will be enrolled based on the RP2D (Recommended Phase 2 Dose) determined from phase I dose escalation data.

    Drug: AMT-116 · Drug: AK112

Interventions

  • AMT-116 is an antibody Drug Conjugate (ADC)

  • DrugAK112

    AK112 is a PD-1/VEGF bispecific tumor immunotherapy drug

06

What researchers measure

Primary outcomes

  1. Phase I: To evaluate the safety and tolerability of the combination of AMT-116 and AK112 in patients with advanced NSCLC and to determine the recommended Phase 2 dose (RP2CD)

    The MTD(Maximum Tolerated Dose) and RP2CD(Recommended Phase 2 Dose) will be determined for expansion using dose limiting toxicities (DLTs) and all other available study data

    Time frame: approximately 10 months

  2. Phase I: Type, incidence and severity of Adverse Events,Dose Limiting Toxicities (DLTs)

    Assess safety and tolerability of AMT-116 and AK112 by the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) version 5.0

    Time frame: approximately 10 months

  3. Phase II: Objective Response Rate(ORR)

    To evaluate the objective response rate (ORR) \[Complete Response (CR) + Partial Response (PR)\] according to the RECIST v1.1

    Time frame: approximately 12 months

  4. Phase II: Type, incidence and severity of Adverse Events

    Assess safety and tolerability of AMT-116 and AK112 by the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) version 5.0

    Time frame: approximately 12 months

Secondary outcomes

  1. Phase I: Overall Response Rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Proportion of patients achieving Complete Response (CR) or Partial Response (PR)

    Time frame: approximately 10 months

  2. Phase I: Disease Control Rate (DCR) according to the RECIST v1.1

    Proportion of patients achieving CR, PR or Stable Disease (SD)

    Time frame: approximately 10 months

  3. Phase I: Progression-free Survival (PFS)Time

    Time from date of start of treatment to date of the first progression or death

    Time frame: approximately 10 months

  4. Phase I: Levels of target expression or Tumor Infiltrating Lymphocyte in tumor tissue

    To assess levels of target expression and Tumor Infiltrating Lymphocyte in tumor tissue

    Time frame: approximately 10 months

  5. Phase I: Concentration of anti-drug antibodies (ADA)

    Immunogenicity profile characterized by concentration of ADAs

    Time frame: approximately 10 months

  6. Phase I: Maximum observed concentration (C[max])

    Pharmacokinetic profile characterized by the maximum observed concentration

    Time frame: approximately 10 months

  7. Phase I: Maximum observed concentration (C[max])

    To characterize the PK profile by analyzing maximum observed

    Time frame: approximately 10 months

  8. Phase II: Disease Control Rate (DCR) according to the RECIST v1.1

    Proportion of patients achieving CR, PR or Stable Disease (SD)

    Time frame: approximately 12 months

  9. Phase II: Progression-free Survival (PFS) according to RECIST v1.1

    Time from date of start of treatment to date of the first progression or death, whichever occurs first.

    Time frame: approximately 12 months

  10. Phase II: Duration of response (DOR)

    DOR is defined as the time from the date of first documented CR or PR to PD or death

    Time frame: approximately 12 months

  11. Phase II: Time to response(TTR)

    The time from the start date of treatment to the date of the first response assessment (PR or CR)

    Time frame: approximately 12 months

  12. Phase II: Levels of target expression in tumor tissue

    To assess levels of target expression in tumor tissue and correlation of those levels with responses and toxicity.

    Time frame: approximately 12months

  13. Phase II: Percentage of patients with ADA formation

    To obtain Percentage of patients with ADA formation

    Time frame: approximately 12 months

  14. Phase II: Maximum observed concentration (C[max])

    To characterize the PK profile by analyzing maximum observed

    Time frame: approximately 12 months

  15. Phase II: Area under the curve (AUC)

    To characterize the PK profile by analyzing area under the curve (AUC) of the ADC, total antibody, and free payload.

    Time frame: approximately 12 months

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 11 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2026
First posted
May 15, 2026
StartActual
Jun 29, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07590531
Lead sponsor
Multitude Therapeutics Inc.
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Jun 29, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Juanjuan Zhu
Contact
juanjuan.zhu@multitudetherapeutics.com
13917933915

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-CD44v9 Antibody-drug Conjugate AMT-116 · Ivonescimab

Start the discussion